Results 161 to 170 of about 122,780 (298)

Generating cytotoxic t lymphocytes against cervical carcinoma with lentivirus transduced antigen presenting cells

open access: bronze, 2000
H. Trent Spencer   +6 more
openalex   +1 more source

Nanoparticle‐Mediated CXCL12–CXCR4 Inhibition Reprograms Macrophages and Suppresses Gastric Carcinoma

open access: yesAdvanced Science, EarlyView.
Molecular mechanism study of self‐assembled M2pep‐Cs NPs/Plerixafor nanoparticles in targeting MΦ reprogramming by regulating the CXCL12–CXCR4 signaling pathway to enhance immune recognition and clearance of GC (Created by BioRender). Abstract Gastric carcinoma (GC) remains a major global health challenge, requiring novel therapeutic approaches.
Qianqian Cao   +9 more
wiley   +1 more source

CD55 may be a new target for colorectal cancer treatment. [PDF]

open access: yesSci Rep
Luo Q   +7 more
europepmc   +1 more source

ACSS2‐Mediated Histone H4 Lysine 12 Crotonylation (H4K12cr) Alleviates Colitis via Enhancing Transcription of CLDN7

open access: yesAdvanced Science, EarlyView.
Histone lysine crotonylation (Kcr) is a highly conserved posttranslational modification implicated with crucial biological processes. This study reveals that ACSS2‐mediated H4K12cr upregulated CLDN7 transcription to strengthen intestinal epithelial barrier.
Ming Yuan   +14 more
wiley   +1 more source

Dusp1 in osteolytic diseases-mechanisms and therapeutic potential. [PDF]

open access: yesSci Rep
Liu B   +8 more
europepmc   +1 more source

A Dual Approach with Organoid and CRISPR Screening Reveals ERCC6 as a Determinant of Cisplatin Resistance in Osteosarcoma

open access: yesAdvanced Science, Volume 12, Issue 28, July 24, 2025.
This study utilizes patient‐derived osteosarcoma organoids and CRISPR screening to identify ERCC6 and HNRNPM as key mediators of cisplatin resistance via the PI3K/AKT pathway and BAX alternative splicing. These findings provide novel insights and potential therapeutic targets for overcoming chemoresistance in osteosarcoma.
Ruiling Xu   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy